NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Clinical trial NCT07502118 · RECRUITING

Trial details

NCT number: NCT07502118
Sponsor: Health Institutes of Turkey
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)Relapsed/Refractory Non-Hodgkin Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL)High-grade B-cell Lymphoma (HGBCL)Follicular Lymphoma ( FL)

Start date: 2025-09-11
Primary completion: 2028-02-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.